Shots:

• Black Belt to get $5.64M (€5M) upfront- equity investment of $2.26M (€2M)- milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s anti-CD38 monoclonal antibody (Mab) TSK011010 program
• The equity investment of $2.26M will be in a newly built subsidiary of Black Belt focusing on novel immuno-oncology targets
• Anti-CD38 Mab program TSK011010 is an IgG1 mAb developed to activate effector T cells and NK cells and will be evaluated in P-I with expected onset in H2’19 or H1’20

Ref: Casi Pharmaceuticals | Image: Casi Pharmaceuticals